In the future, NKT engineering with CARs could result in an enhanced antitumor efficacy in solid tumor settings, exploiting the synergism of CAR activity with their capability to kill immunosuppressive CD1d-expressing tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells [73]. The gene discussed is CD1D; the disease is neoplasm.